The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic fle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback